196 related articles for article (PubMed ID: 34885691)
1. Enhanced Anti-Tumor Effect of Folate-Targeted FA-AMA-hyd-DOX Conjugate in a Xenograft Model of Human Breast Cancer.
Liao TT; Han JF; Zhang FY; Na R; Ye WL
Molecules; 2021 Nov; 26(23):. PubMed ID: 34885691
[TBL] [Abstract][Full Text] [Related]
2. Cellular uptake and antitumor activity of DOX-hyd-PEG-FA nanoparticles.
Ye WL; Du JB; Zhang BL; Na R; Song YF; Mei QB; Zhao MG; Zhou SY
PLoS One; 2014; 9(5):e97358. PubMed ID: 24828815
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of a new pH-sensitive folate-doxorubicin conjugate and its antitumor activity in vitro.
Ye WL; Teng ZH; Liu DZ; Cui H; Liu M; Cheng Y; Yang TH; Mei QB; Zhou SY
J Pharm Sci; 2013 Feb; 102(2):530-40. PubMed ID: 23169439
[TBL] [Abstract][Full Text] [Related]
4. Folate/N-acetyl glucosamine conjugated mesoporous silica nanoparticles for targeting breast cancer cells: A comparative study.
Kumar P; Tambe P; Paknikar KM; Gajbhiye V
Colloids Surf B Biointerfaces; 2017 Aug; 156():203-212. PubMed ID: 28531877
[TBL] [Abstract][Full Text] [Related]
5. Mitochondria and Nucleus Dual Delivery System To Overcome DOX Resistance.
Cui H; Huan ML; Ye WL; Liu DZ; Teng ZH; Mei QB; Zhou SY
Mol Pharm; 2017 Mar; 14(3):746-756. PubMed ID: 28146635
[TBL] [Abstract][Full Text] [Related]
6. Actively targeted delivery of doxorubicin to bone metastases by a pH-sensitive conjugation.
Ye WL; Zhao YP; Na R; Li F; Mei QB; Zhao MG; Zhou SY
J Pharm Sci; 2015 Jul; 104(7):2293-303. PubMed ID: 25980534
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo antitumor activity of a novel pH-activated polymeric drug delivery system for doxorubicin.
Huan M; Zhang B; Teng Z; Cui H; Wang J; Liu X; Xia H; Zhou S; Mei Q
PLoS One; 2012; 7(9):e44116. PubMed ID: 23028490
[TBL] [Abstract][Full Text] [Related]
8. Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation.
Alibolandi M; Abnous K; Sadeghi F; Hosseinkhani H; Ramezani M; Hadizadeh F
Int J Pharm; 2016 Mar; 500(1-2):162-78. PubMed ID: 26802496
[TBL] [Abstract][Full Text] [Related]
9. Theranostic pH-sensitive nanoparticles for highly efficient targeted delivery of doxorubicin for breast tumor treatment.
Pan C; Liu Y; Zhou M; Wang W; Shi M; Xing M; Liao W
Int J Nanomedicine; 2018; 13():1119-1137. PubMed ID: 29520140
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of a folate receptor-targeted immunoglobulin G-doxorubicin conjugate.
Yang T; Xu L; Li B; Li W; Ma X; Fan L; Lee RJ; Xu C; Xiang G
Int J Nanomedicine; 2017; 12():2505-2515. PubMed ID: 28408821
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect of folate-targeted liposomal doxorubicin in KB tumor-bearing mice after intravenous administration.
Riviere K; Huang Z; Jerger K; Macaraeg N; Szoka FC
J Drug Target; 2011 Jan; 19(1):14-24. PubMed ID: 20353291
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier.
Lu J; Zhao W; Huang Y; Liu H; Marquez R; Gibbs RB; Li J; Venkataramanan R; Xu L; Li S; Li S
Mol Pharm; 2014 Nov; 11(11):4164-78. PubMed ID: 25265550
[TBL] [Abstract][Full Text] [Related]
14. Folate-targeted polymersomes loaded with both paclitaxel and doxorubicin for the combination chemotherapy of hepatocellular carcinoma.
Zhu D; Wu S; Hu C; Chen Z; Wang H; Fan F; Qin Y; Wang C; Sun H; Leng X; Kong D; Zhang L
Acta Biomater; 2017 Aug; 58():399-412. PubMed ID: 28627436
[TBL] [Abstract][Full Text] [Related]
15. Folate and TAT peptide co-modified liposomes exhibit receptor-dependent highly efficient intracellular transport of payload in vitro and in vivo.
Zhu Y; Cheng L; Cheng L; Huang F; Hu Q; Li L; Tian C; Wei L; Chen D
Pharm Res; 2014 Dec; 31(12):3289-303. PubMed ID: 24858397
[TBL] [Abstract][Full Text] [Related]
16. Dual subcellular compartment delivery of doxorubicin to overcome drug resistant and enhance antitumor activity.
Song YF; Liu DZ; Cheng Y; Liu M; Ye WL; Zhang BL; Liu XY; Zhou SY
Sci Rep; 2015 Nov; 5():16125. PubMed ID: 26530454
[TBL] [Abstract][Full Text] [Related]
17. pH-sensitive Au-BSA-DOX-FA nanocomposites for combined CT imaging and targeted drug delivery.
Huang H; Yang DP; Liu M; Wang X; Zhang Z; Zhou G; Liu W; Cao Y; Zhang WJ; Wang X
Int J Nanomedicine; 2017; 12():2829-2843. PubMed ID: 28435261
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of doxorubicin α-linolenic acid conjugate and evaluation of its antitumor activity.
Liang CH; Ye WL; Zhu CL; Na R; Cheng Y; Cui H; Liu DZ; Yang ZF; Zhou SY
Mol Pharm; 2014 May; 11(5):1378-90. PubMed ID: 24720787
[TBL] [Abstract][Full Text] [Related]
19. pH-triggered intracellular release from actively targeting polymer micelles.
Guo X; Shi C; Wang J; Di S; Zhou S
Biomaterials; 2013 Jun; 34(18):4544-54. PubMed ID: 23510854
[TBL] [Abstract][Full Text] [Related]
20. Folate-modified poly(2-ethyl-2-oxazoline) as hydrophilic corona in polymeric micelles for enhanced intracellular doxorubicin delivery.
Qiu LY; Yan L; Zhang L; Jin YM; Zhao QH
Int J Pharm; 2013 Nov; 456(2):315-24. PubMed ID: 24016742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]